TAK-779 Catalog No.:M10030-10 suppresses human Th17 responses

suppresses human Th17 responses

also known as (R)-Baclofen

Jinnin M et al

A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors

4 mg/kg MK-8776 S-isomer is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or MK-8776 S-isomer alone

TAK-779 Catalog No.:M10030-10 suppresses human Th17 responsesTAK 779 is a C C chemokine receptor type 5 (CCR5) receptor antagonist potentially for the treatment of HIV infection. Treatment with TAK 779 reduced incidence and severity of experimental autoimmune encephalomyelitis. It strongly inhibited migration of CXCR3 CCR5 bearing CD4+, CD8+ and CD11b+ leukocytes to the CNS. TAK 779 did not reduce proliferation of anti myelin oligodendrocyte glycoprotein T cells, the production of IFN gamma by T cells or CXCR3